You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
|
|---|---|
| Published in |
Frontiers in oncology, April 2021
|
| DOI | 10.3389/fonc.2021.638482 |
| Pubmed ID | |
| Authors |
Tomás Pascual, Mafalda Oliveira, Eva Ciruelos, Meritxell Bellet Ezquerra, Cristina Saura, Joaquin Gavilá, Sonia Pernas, Montserrat Muñoz, Maria J. Vidal, Mireia Margelí Vila, Juan M. Cejalvo, Blanca González-Farré, Martin Espinosa-Bravo, Josefina Cruz, Francisco Javier Salvador-Bofill, Juan Antonio Guerra, Ana María Luna Barrera, Miriam Arumi de Dios, Stephen Esker, Pang-Dian Fan, Olga Martínez-Sáez, Guillermo Villacampa, Laia Paré, Juan M. Ferrero-Cafiero, Patricia Villagrasa, Aleix Prat |
X Demographics
The data shown below were collected from the profiles of 39 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 14 | 36% |
| United States | 3 | 8% |
| United Kingdom | 2 | 5% |
| Italy | 2 | 5% |
| Belgium | 2 | 5% |
| Mexico | 1 | 3% |
| Ireland | 1 | 3% |
| El Salvador | 1 | 3% |
| Switzerland | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 11 | 28% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 22 | 56% |
| Practitioners (doctors, other healthcare professionals) | 11 | 28% |
| Scientists | 5 | 13% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 16% |
| Student > Postgraduate | 4 | 11% |
| Student > Ph. D. Student | 4 | 11% |
| Student > Bachelor | 3 | 8% |
| Other | 3 | 8% |
| Other | 4 | 11% |
| Unknown | 13 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 35% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Design | 2 | 5% |
| Sports and Recreations | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 16 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2021.
All research outputs
#1,523,998
of 25,387,668 outputs
Outputs from Frontiers in oncology
#276
of 22,433 outputs
Outputs of similar age
#40,475
of 452,849 outputs
Outputs of similar age from Frontiers in oncology
#13
of 1,228 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,433 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,849 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1,228 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.